Manx ministers' roadshow a 'chance to hear public views'
Taking place at Ramsey Grammar School, Ballakermeen High School in Douglas, Castle Rushen High School in Castletown, Queen Elizabeth II High School in Peel on consecutive days between 17:30 until 20:00 BST.Each session will begin with a speech from Cannan, followed by the chance to ask questions and one-to-one time with ministers.
'Thought-provoking'
The chief minister said key themes from last year's events included the tax rise, the cost of public services, travel on and off the island, healthcare and mental health services.Cannan said he hoped to use the latest series to explain the progress made on those matters since.While he did not want to "prejudge" what matters would be raised, he said he was expecting the economy, the cost of immigration and security as well as more questions about healthcare to be raised by the public.However, he said there were "always questions that we perhaps aren't anticipating, which can often be revealing and thought-provoking".He said the events also enabled people to "highlight where negative impacts were taking place", which "provided an opportunity to reflect on that".The sessions, which saw about 400 people attend overall last year, were also an "opportunity" for ministers to go out to different parts of the island to "engage with people they would not ordinarily see and hear the challenges they face".
Read more stories from the Isle of Man on the BBC, watch BBC North West Tonight on BBC iPlayer and follow BBC Isle of Man on Facebook and X.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
14 hours ago
- Daily Mail
Trump demands UK pharmaceutical giants to lower drug costs sparking fears NHS could pay the price if they refuse
Donald Trump has demanded UK pharmaceutical giants lower prices for America and suggested charging others to make up the difference. He said if they didn't, the US would deploy 'every tool in our arsenal' to protect families from 'continued abusive drug prices', sparking fears the NHS will end up paying more. Mr Trump suggested he would use tariffs to push through higher prices if countries resisted. In May Mr Trump signed an executive order demanding drugmakers cut US medicine prices to match those abroad. Yesterday in a letter to 17 pharma companies he said he expected them to deliver on measures by September 29. He asked them to apply 'most favoured nation' pricing to Medicaid, the US health programme for people on low incomes. Mr Trump also asked drugmakers to offer new medicines at the same price in the US as in other developed countries. He said: 'Our citizens pay massively higher prices than other nations pay for the same exact pill... subsidizing socialism aboard [abroad].' British pharma companies AstraZeneca and GSK were among the recipients. Others included Eli Lilly, Johnson & Johnson, Pfizer and Sanofi. The UK Government said it would 'continue to work closely with the US to get the best deal for our pharma industry and deliver mutual benefits for both our countries'.
Reuters
21 hours ago
- Reuters
US states sue over Trump's targeting of providers of transgender youth medical care
Aug 1 (Reuters) - A coalition of Democratic-led states filed a lawsuit on Friday seeking to block policies the U.S. Department of Justice adopted under President Donald Trump to crack down on providers of medical gender-affirming care for transgender youth. Sixteen states, along with the District of Columbia, in a lawsuit, opens new tab filed in federal court in Boston, argued Trump unconstitutionally trampled on their rights to regulate medicine with an executive order in January that directed prosecutors to prioritize investigations of transgender youth care. The executive order, which also directed an end to all federal funding or support for healthcare that aids the transition of transgender youth, formed the basis of two recent Justice Department directives that the lawsuit also challenges. Those policies include an April memo from U.S. Attorney General Pam Bondi directing prosecutors to investigate cases involving procedures that she said would violate a federal law barring "female genital mutilation." Bondi also directed the department to launch civil investigations into medical providers and pharmaceutical companies that manufacture and distribute puberty blockers and hormones prescribed by doctors. The Justice Department last month said it sent more than 20 subpoenas to doctors and clinics involved in performing transgender medical procedures on children. Democratic state attorneys general argue the Justice Department's efforts are part of a campaign by the Republican president's administration to intimidate healthcare providers into ceasing to provide such treatments to people under the age of 19, even in states where such treatments are legal. "This administration is ruthlessly targeting young people who already face immense barriers just to be seen and heard, and are putting countless lives at risk in the process," New York Attorney General Letitia James said in a statement. The states argue that by invoking the female genital mutilation statute, the Food, Drug, and Cosmetic Act, and the False Claims Act, the Justice Department is relying on laws that were never intended to be used to address the conduct at issue. They say Trump's executive order violates the states' rights under the U.S. Constitution's 10th Amendment. Regulation of the practice of medicine has long been left to the states. Conservative lawmakers in 25 states have in recent years adopted bans on various forms of gender-affirming care for adolescents. The U.S. Supreme Court in June upheld one such ban in Tennessee, delivering a major setback for transgender rights advocates.
The Guardian
a day ago
- The Guardian
Sorry America, but it's not Australia's fault that your healthcare system is failing you
If I were president of the United States, I would certainly be concerned about the cost and performance of the country's healthcare system. The grim statistics are well known. As of 2022, the US spent $12,555 per person on healthcare, almost twice as much as other wealthy countries, including Australia. That gap alone cancels out about half of the difference in income per person between the US and Australia, according to World Bank estimates. Higher expenditure on healthcare would not be a problem if it delivered a healthier population. But this is not the case. The US has one of the lowest life expectancies of any rich country. And even though more Americans die young, those who survive have worse health than elsewhere. Americans suffer from chronic diseases like diabetes, asthma and depression at around twice the (age-adjusted) rate of other rich countries. This gap is too large to be accounted for by specific causes like gun violence or drug overdoses, or even unequal income distribution. The US has worse health outcomes at every point on the income distribution scale than other rich countries, even though those at the upper end have much higher incomes. Sign up: AU Breaking News email And the problem is getting worse. The US saw declining life expectancy in the years after 2014 and, unlike other countries, saw a late, limited recovery from the increased death rate after the onset of the Covid pandemic. There's not much hope for rapid progress in US health outcomes. The destruction of US public health infrastructure through budget cuts, the gutting of key agencies such as the Center for Disease Control and the appointment of notorious anti-vaxxer RFK Jr as secretary of health and human services will only make matters worse. It's unsurprising then that President Donald Trump is looking at the cost side of the equation. As might be expected he has raised, again, the perennial grievances of US health policy. This is the fact that Americans pay far more for prescription medicines than do citizens of other countries where prices are controlled through mechanisms like Australia's Pharmaceutical Benefits Scheme (PBS). And, given his grievance-based approach to the world in general, it is no surprise that his latest statement on the topic describes Australia and other countries as 'freeloaders' on the US. The US government is, of course, entirely within its rights to set its own policy regarding the pricing of prescription drugs. The US Department of Veterans Affairs already has a program similar to the PBS, under which it pays about half as much of the typical US price. There is no reason this couldn't be extended to the entire US Medicare system, except that the result would be to close down 1,000 or more private plans, each with their own lobbyists. And with a bit more effort, the US could establish its own version of the PBS, covering all Americans. Quite possibly, faced with lower prices in the US, pharmaceutical companies might demand higher returns from other countries including Australia. But a systematic reform of this kind is beyond the capacity of the Trump administration. Instead we have seen the typical Trumpian claim that other countries are benefiting unfairly from medical research done in the US. This was arguably true in the second half of the 20th century when the US was the undoubted centre of global medical research, most notably through the National Institutes of Health. But funding for the NIH (adjusted for inflation) peaked in 2004, and has suffered from decades of financial stringency. Meanwhile, the US share of genuine innovations, measured by 'new molecular entities' has declined and is no longer notably larger (relative to GDP) than that of leading European innovators. The development of semaglutide (Ozempic and Wegovy) treatments for obesity and diabetes by Danish firm Novo Nordisk is a notable example of a drug of particular importance to the US being developed in Europe. More generally, if Trump wants to import ideas like the PBS into the US system, Australia has plenty to offer. Australia's Medicare system, combining a single-payer universal scheme for standard healthcare with private insurance and fee-for-service medicine as an upper tier, could provide a politically palatable way of delivering the US demand for 'Medicare for all' without destroying the private sector. But of course, this isn't the Trump way. What we will doubtless see, as in the recent tariff negotiations, is a series of bullying demands, resulting in triumphant announcements of magnificent deals, which turn out, on closer inspection, to be largely illusory. The bigger lesson for Australia in all of this is that, as with China, we need to treat the US not as an ally or friend but as a trading partner which will seek to push us around whenever possible. The correct response, again as with China, is to stand our ground until the other side sees the pointlessness of bullying and the mutual benefits of free exchange. John Quiggin is a professor at the University of Queensland's school of economics
